Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Julia Kollewe

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Packages of Ozempic and Wegovy by Novo Nordisk
CagriSema is expected to lead to greater weight loss than Novo Nordisk’s popular Wegovy and Ozempic jabs. Photograph: Ida Marie Odgaard/EPA

The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.

Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.